To date, OncoSec’s immunotherapy platform, ImmunoPulse®, focuses on the delivery of DNA-based interleukin-12 (IL-12), a naturally occurring protein with immune-stimulating functions. The treatment is designed to produce a controlled, localized expression of IL-12 in the tumor microenvironment, which in turn, enables the immune system to target and attack tumors throughout the body.
OncoSec is currently investigating ImmunoPulse® IL-12 for treatment of metastatic melanoma and triple negative breast cancer. As the company continues to evaluate ImmunoPulse® IL-12 in these current indications, OncoSec is developing new immune-targeting agents, investigating additional tumor indications, and evaluating combination-based immunotherapy approaches.
Cancer is identified in the body.
DNA-based interleukin-12 (IL-12), a naturally occurring protein, is injected directly into the tumor.
The applicator supplies a sequence of short-duration electrical pulses through a series of needles.
Electrical pulses result in increased permeability of the cell membrane, allowing DNA-based IL-12 to enter.
DNA-based IL-12 is expressed in the local tumor microenvironment.
IL-12 drives local inflammatory response in the tumor.
Immune cells are educated to recognize the patient’s cancer.
Educated immune cells identify and attack tumors throughout the body.